BMT CTN 1703/1801: A Randomized, Multi-Center, Phase III Trial of Tacrolimus/ Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (PROGRESS III)/Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)

Comparing Graft-versus-Host Disease (GVHD) Prophylaxis Regimens for Survival Outcomes

Recruiting
18 years - 100 years
All
1 Location

Brief description of study.

The primary objective of the trial is to compare 1 year GVHD-free, relapse-free survival (GRFS) between the two GVHD prophylaxis regimens.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myelodysplasia,Diffuse Large B Cell Lymphoma,Chronic Myelogenous Leukemia,Hodgkin Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Acute Leukemia,Follicular Lymphoma,Mantle Cell Lymphoma
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Cardiac function: Left ventricular ejection fraction at least 45%.
  • Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant (see Section 2.6.4 for definition of postmenopausal).
  • Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant.

For a full list of participation criteria, please visit clinicaltrials.gov.

 

Updated on 19 Feb 2024. Study ID: 1903006145 (BMTCTN1703/1801)

This study investigates two different methods for preventing graft-versus-host disease (GVHD) in patients who have undergone a transplant. GVHD is a condition where the transplanted cells attack the recipient's body. The study aims to see which method better supports survival without GVHD or cancer relapse over one year.

Participants will undergo specific procedures to monitor their health and the effectiveness of the GVHD prevention methods. These procedures help ensure that the investigational approaches are safe and effective for patients.

  • Who can participate: Adults with a left ventricular ejection fraction of at least 45% can participate. Women must use two effective birth control methods or abstain from heterosexual intercourse, while men must use barrier contraception or abstain.
  • Study details: Participants will receive one of two GVHD prevention treatments. A placebo is not involved in this study.
  • Study Timelines: The study will last 1 year.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here